Efineptakin alfa

Generic Name: Efineptakin alfa

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2026634-47-7

Unique Ingredient Identifier: 3K3WC6MT6P

Background: Efineptakin alfa (also known as NT-I7) is a long-acting human interleukin-7 (IL-7) fusion protein that promotes T-cell development, contributing to the immune response. Compared to endogenous IL-7, NT-I7 is more stable and potent, has a longer half-life, and has better bioavailability. This drug is currently being investigated in the areas of oncology, immun...

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Phase 2

Recruiting

Conditions: High Grade Astrocytic Tumor
Recurrent Glioblastoma, IDH-Wildtype
Recurrent Gliosarcoma

Interventions: Procedure: Biospecimen Collection
Biological: Efineptakin alfa
Biological: Pembrolizumab
Procedure: Biopsy

First Posted Date: 2022-07-20

Last Posted Date: 2024-12-04

Lead Sponsor: Mayo Clinic

Target Recruit Count: 44

Registration Number: NCT05465954

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Phase 1

Recruiting

Conditions: Refractory High Grade B-Cell Lymphoma
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Refractory Diffuse Large B-cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma

Interventions: Drug: Efineptakin alfa
Drug: Tisagenlecleucel
Drug: Axicabtagene ciloleucel
Drug: Lisocabtagene Maraleucel

First Posted Date: 2021-10-13

Last Posted Date: 2024-02-22

Lead Sponsor: NeoImmuneTech

Target Recruit Count: 57

Registration Number: NCT05075603

Locations: 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit, Michigan, United States

and more 1 locations

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Phase 2

Active, not recruiting

Conditions: Non Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Carcinoma, Non-Small-Cell Lung
Non-Small Cell Lung Cancer
Nonsmall Cell Lung Cancer

Interventions: Drug: efineptakin alfa
Drug: Atezolizumab

First Posted Date: 2021-08-02

Last Posted Date: 2024-03-05

Lead Sponsor: NeoImmuneTech

Target Recruit Count: 83

Registration Number: NCT04984811

Locations: 🇺🇸
Zangmeister Cancer Center, Columbus, Ohio, United States
🇺🇸
Tennessee Oncology - Nashville, Nashville, Tennessee, United States
🇺🇸
University of South Alabama, Mobile, Alabama, United States

and more 19 locations

NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy

Early Phase 1

Recruiting

Conditions: Progressive Multifocal Leukoencephalopathy

Interventions: Drug: NT-I7

First Posted Date: 2021-03-04

Last Posted Date: 2024-12-19

Lead Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Target Recruit Count: 12

Registration Number: NCT04781309

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma

Phase 1

Terminated

Conditions: Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)

Interventions: Drug: NT-I7
Drug: Nivolumab

First Posted Date: 2020-10-20

Last Posted Date: 2024-08-16

Lead Sponsor: NeoImmuneTech

Target Recruit Count: 10

Registration Number: NCT04594811

Locations: 🇵🇱
Centrum Medyczne Klara, Czestochowa, Poland
🇵🇱
Pratia Poznań, Skorzewo, Poland
🇺🇸
The Center for Cancer & Blood Disorders, Fort Worth, Texas, United States

and more 3 locations

Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)

Phase 1

Withdrawn

Conditions: SARS-CoV-2
COVID-19

Interventions: Drug: Placebo
Drug: NT-I7
Procedure: Blood for research purposes
Procedure: Nasopharyngeal, oropharyngeal, or saliva swab
Procedure: Blood for pharmacokinetic samples
Procedure: Blood for anti-drug antibody (ADA)

First Posted Date: 2020-08-04

Last Posted Date: 2021-08-05

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT04498325

NT-I7 (Efineptakin Alfa) in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Triple Negative Breast Cancer
Any Advanced Solid Tumors
Microsatellite Stable Colorectal Cancer
Pancreatic Cancer
Ovarian Cancer
Non Small Cell Lung Cancer
Small Cell Lung Cancer

Interventions: Drug: NT-I7
Drug: pembrolizumab (KEYTRUDA®)

First Posted Date: 2020-04-03

Last Posted Date: 2024-10-07

Lead Sponsor: NeoImmuneTech

Target Recruit Count: 215

Registration Number: NCT04332653

Locations: 🇺🇸
Moffit Cancer Center, Tampa, Florida, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States

and more 5 locations

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Phase 1

Terminated

Conditions: Melanoma
Merkel Cell Carcinoma
Cutaneous Squamous Cell Carcinoma

Interventions: Drug: NT-I7
Drug: atezolizumab

First Posted Date: 2019-04-03

Last Posted Date: 2024-02-22

Lead Sponsor: NeoImmuneTech

Target Recruit Count: 31

Registration Number: NCT03901573

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Dana Farber, Boston, Massachusetts, United States
🇺🇸
MGH, Boston, Massachusetts, United States

and more 5 locations

rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide

Phase 1

Recruiting

Conditions: Glioma

Interventions: Drug: Placebo
Drug: rhIL-7-hyFc
Drug: Temozolomide
Radiation: Radiation therapy
Procedure: Blood sample

First Posted Date: 2018-09-27

Last Posted Date: 2024-01-12

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 70

Registration Number: NCT03687957

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy